Printer Friendly

CAMBRIDGE NEUROSCIENCE ELECTS CEO OF NEW ENGLAND TELEPHONE AND BANK OF BOSTON OFFICIAL TO BOARD OF DIRECTORS

 CAMBRIDGE NEUROSCIENCE ELECTS CEO OF NEW ENGLAND TELEPHONE AND
 BANK OF BOSTON OFFICIAL TO BOARD OF DIRECTORS
 CAMBRIDGE, Mass., June 1 /PRNewswire/ -- Cambridge NeuroScience, Inc. (NASDAQ: CNSI) announced today that it has elected Paul O'Brien, president and chief executive officer of New England Telephone Company, and Ira Jackson, executive director of external affairs and marketing at the Bank of Boston, to its board of directors. The two appointments bring to eight the number of directors at the Cambridge-based biopharmaceutical company.
 As head of New England Telephone, O'Brien oversees a corporation with assets of $8 billion and which employs nearly 23,000 people in New England. In addition to his position at New England Telephone, O'Brien is chairman of the Greater Boston Chamber of Commerce. He is also on the boards of the First National Bank of Boston and the Massachusetts Business Roundtable. O'Brien was born in New York City and holds degrees from Manhattan College and New York University.
 Jackson is a senior vice president of the Bank of Boston and an executive officer of the corporation, overseeing external affairs, including governmental relations, advertising and marketing, economic analysis and corporate communications. In addition, Jackson serves on the boards of the Bank of Vermont, Rhode Island Hospital Trust and Casco Northern Bank, and on a number of non-profit boards, including Morgan Memorial Goodwill Industries. Jackson was born in Chelsea, Mass., and received his undergraduate degree from Harvard University, as well as a masters degree in public administration from the Kennedy School of Government.
 "We are very fortunate to have attracted to our board two individuals of the highest caliber who bring to the company a wealth of business acumen and experience," said Alan J. Dalby, chairman and chief executive officer. "These individuals will greatly enhance our board's decision-making ability during what we believe will be Cambridge NeuroScience's most exciting stage of development."
 Cambridge NeuroScience is a leading neuroscience company engaged in the discovery and development of proprietary pharmaceutical products to treat a variety of severe neurological and psychiatric disorders, including stroke, traumatic brain injury, schizophrenia, diabetic peripheral neuropathies, Alzheimer's disease and amyotrophic lateral sclerosis (Lou Gehrig's disease).
 -0- 6/1/92
 /CONTACT: John T. Smith of Cambridge NeuroScience, 617-225-0600, ext. 151/
 (CNSI) CO: Cambridge NeuroScience, Inc. ST: Massachusetts IN: MTC SU: PER


SH -- NE005 -- 5599 06/01/92 10:36 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 1, 1992
Words:390
Previous Article:GRC INTERNATIONAL ANNOUNCES SUBSIDIARY PARTICIPATION IN MAJOR NAVAL ELECTRONICS CONTRACT
Next Article:LEVA BECOMES CHAIRMAN OF GPU AS KUHNS RETIRES


Related Articles
FLEET BANK OF MASSACHUSETTS ANNOUNCES ADDITIONS TO BOARD
ROBERT J. MURRAY APPOINTED BOARD MEMBER FOR FLEET BANK OF MASSACHUSETTS
NEW CHAIRMAN ELECTED EFFECTIVE JULY 1ST
POLAROID'S BOOTH ELECTED CHAIRMAN OF INROADS NATIONAL BOARD OF DIRECTORS
ROBERT MCBURNEY PH.D., PROMOTED TO CHIEF SCIENTIFIC OFFICER, SENIOR VP RESEARCH FOR CAMBRIDGE NEUROSCIENCE, INC.
CAMBRIDGE NEUROSCIENCE EXPANDS CLINICAL STUDIES OF CERESTAT(TM) IN STROKE PATIENTS
CAMBRIDGE CITY COUNCILOR CONVICTED ON CONSPIRACY CHARGES, U.S. ATTORNEY'S OFFICE ANNOUNCES
CAMBRIDGE NEUROSCIENCE BEGINS MULTINATIONAL DOSE-FINDING STUDY OF CERESTAT(TM) IN STROKE PATIENTS
NLC Council on Youth Convenes to Frame Agenda.
Joseph P. Campanelli Elected Chairman of Massachusetts Business Roundtable.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters